See more : Emperor Capital Group Limited (0717.HK) Income Statement Analysis – Financial Results
Complete financial analysis of OTR Acquisition Corp. (OTRAU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OTR Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
- Masonite International Corporation (DOOR) Income Statement Analysis – Financial Results
- Rajoo Engineers Limited (RAJOOENG.BO) Income Statement Analysis – Financial Results
- Nuvation Bio Inc. (NUVB-WT) Income Statement Analysis – Financial Results
- Fwusow Industry Co., Ltd. (1219.TW) Income Statement Analysis – Financial Results
- Deutsche Börse AG (DBOEY) Income Statement Analysis – Financial Results
OTR Acquisition Corp. (OTRAU)
About OTR Acquisition Corp.
As of May 19, 2022, OTR Acquisition Corp. was acquired by Comera Life Sciences Holdings, Inc., in a reverse merger transaction. OTR Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Miami, Florida.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 |
| Other Expenses | 1.05M | -208.69K |
| Operating Expenses | 1.05M | -208.69K |
| Cost & Expenses | 1.05M | -208.69K |
| Interest Income | 37.68K | 0.00 |
| Interest Expense | -5.74M | 0.00 |
| Depreciation & Amortization | 5.74M | 9.16K |
| EBITDA | 4.69M | -199.53K |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -1.05M | -208.69K |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.74M | 9.16K |
| Income Before Tax | 4.69M | -199.53K |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | -5.74M | 0.00 |
| Net Income | 10.43M | -199.53K |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | 0.79 | -0.02 |
| EPS Diluted | 0.79 | -0.02 |
| Weighted Avg Shares Out | 13.24M | 13.24M |
| Weighted Avg Shares Out (Dil) | 13.24M | 13.24M |
6 Stocks Halted In Wednesday's Session: Here's Why
Biologic Medicines-Focused Comera Life Sciences Turns To SPAC For NASDAQ Debut
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
Source: https://incomestatements.info
Category: Stock Reports